Enzymatic synthesis of c-di-GMP using inclusion bodies of Thermotoga maritima full-length diguanylate cyclase

Коровашкина, А С; Рымко, А. Н.; Квач, С В; Зинченко, А. И.

doi:10.1016/j.jbiotec.2012.12.006

Cited by 16 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the enzymatic synthesis of cyclic-diGMP has been reported by several groups [9], [29], [40], [51], [58], our system offers clear advantages over other reported diguanylate cyclases. With these other enzymatic syntheses, it has not been possible to produce large amounts of cyclic-diGMP because most diguanylate cyclases are regulated by product inhibition.…”

Section: Resultsmentioning

confidence: 95%

“…Despite this, however, product inhibition was still observed at concentrations of GTP greater than 0.8 mM [40]. Recently, this variant was engineered to contain the protein's hydrophobic domain and the resulting enzyme was purified from inclusion bodies [29]. This modified T. maritima protein displayed improved enzymatic activity, producing 500 μM of cyclic-diGMP with 2.5 μM of protein.…”

Section: Resultsmentioning

confidence: 99%

“…Enzymatic synthesis of cyclic-diGMP has been reported by several groups using diguanylate cyclases [9], [29], [40], [51], [58]. In most cases, the enzymes used by these groups contain an RxxD product-inhibition site that limits the amount of cyclic-diGMP produced.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modification of a bi-functional diguanylate cyclase-phosphodiesterase to efficiently produce cyclic diguanylate monophosphate

Nesbitt

Arora

Johnson

et al. 2015

Biotechnology Reports

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Modification of a bi-functional diguanylate cyclase-phosphodiesterase to efficiently produce cyclic diguanylate monophosphate

Nesbitt

Arora

Johnson

et al. 2015

Biotechnology Reports

View full text Add to dashboard Cite

show abstract

“…Among the chemistry reported for the synthesis of c-di-GMP analogs, some features are of important consideration: versatility of the chemistry, ease to scale up the process, and to purify the final product. It is worth noting that c-di-GMP [ 34 , 35 ], c-di-araGMP and c-di-dGMP [ 36 ], and other analogs [ 37 ], 3′3′-cGAMP and 2′3′-cGAMP [ 38 , 39 ] and their analogs [ 39 , 40 ] have also been generated enzymatically.…”

Section: C-di-gmp and Analogs Generated To Datementioning

confidence: 99%

The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development

Yan

Chen

2021

Vaccines

View full text Add to dashboard Cite

Cyclic dinucleotides (CDNs), originally discovered as bacterial second messengers, play critical roles in bacterial signal transduction, cellular processes, biofilm formation, and virulence. The finding that CDNs can trigger the innate immune response in eukaryotic cells through the stimulator of interferon genes (STING) signalling pathway has prompted the extensive research and development of CDNs as potential immunostimulators and novel molecular adjuvants for induction of systemic and mucosal innate and adaptive immune responses. In this review, we summarize the chemical structure, biosynthesis regulation, and the role of CDNs in enhancing the crosstalk between host innate and adaptive immune responses. We also discuss the strategies to improve the efficient delivery of CDNs and the recent advance and future challenges in the development of CDNs as potential adjuvants in prophylactic vaccines against infectious diseases and in therapeutic vaccines against cancers.

show abstract

“…Research was conducted at facilities of Vitebsk municipal veterinary station and Vitebsk State Academy of Veterinary Medicine. Test specimen of cyclic di-GMP was produced by enzymatic procedure at laboratory of molecular biotechnology of Institute of Microbiology, NAS of Belarus using diguanylate cyclase enzyme isolated from recombinant bacterial strain [21].…”

mentioning

confidence: 99%

Biopreparation for in Situ Antitumor Vaccination

Зинченко

Birichevskaya

Shchokolova

et al. 2021

ASJ

View full text Add to dashboard Cite

The present study is focused on the first attempt to use an enzymatically produced biological preparation of cyclic diguanosine monophosphate (cyclic di-GMP) for the therapy of animal cancer. Feline breast carcinoma was chosen as the test model. The preparation was administered intratumorally to induce the immunogenic death of a part of the cancer cells and thus carry out the so-called in situ antitumor vaccination. Preliminary results indicate good therapeutic prospects of studied biopreparation for animal cancer treatment. In conclusion, the expedience of further trials of cyclic di-GMP preparation for in situ antitumor vaccination was stated. The need to supplement this mono-preparation with another immunostimulating adjuvant characterized by a mechanism of action distinct from that exhibited by cyclic di-GMP was emphasized. DNA preparation comprising the so-called immunostimulating CpG motifs was provided as an example of such compound.

show abstract

Enzymatic synthesis of c-di-GMP using inclusion bodies of Thermotoga maritima full-length diguanylate cyclase

Cited by 16 publications

References 26 publications

Modification of a bi-functional diguanylate cyclase-phosphodiesterase to efficiently produce cyclic diguanylate monophosphate

Modification of a bi-functional diguanylate cyclase-phosphodiesterase to efficiently produce cyclic diguanylate monophosphate

The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development

Biopreparation for in Situ Antitumor Vaccination

Contact Info

Product

Resources

About